# Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme

> **NCT00227032** · PHASE1 · TERMINATED · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 10 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** erlotinib hydrochloride

## Key facts

- **NCT ID:** NCT00227032
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-09
- **Primary completion:** 2008-02
- **Final completion:** 2008-03
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Loss of funding
- **Last updated:** 2012-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00227032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00227032, "Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00227032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*